The Adenosinergic System : A Non-Dopaminergic Target in Parkinson’s Disease /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2015.
|
| Edición: | 1st ed. 2015. |
| Colección: | Current Topics in Neurotoxicity,
10 |
| Materias: |
Tabla de Contenidos:
- Adenosine A2A receptors: localization and function
- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer
- Adenosine A2A receptor antagonists in drug development
- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease
- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease
- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection
- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies
- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism
- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations
- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease
- Imaging Studies with A2A Receptor Antagonists
- Caffeine and neuroprotection in Parkinson's disease
- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease
- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease
- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.